Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dose Size and Dosing Frequency: Determination Methods01:21

Dose Size and Dosing Frequency: Determination Methods

Determining the optimal dose size and dosing frequency in pharmacotherapy is crucial for achieving therapeutic effectiveness while minimizing adverse effects. This article explores the methodologies employed in determining these parameters, focusing on their significance and interplay to tailor dosing regimens.Dose Size: Dose size refers to the amount of a drug administered in a single dose. It is determined based on the drug's pharmacodynamics and pharmacokinetics properties and...
Dose Response Curve: Conventional Versus Nonmonotonic01:21

Dose Response Curve: Conventional Versus Nonmonotonic

The correlation between a drug's dosage and its impact on a biological system is a cornerstone of pharmacology and toxicology. Conventional dose–response curves, which include graded and quantal relationships, are key to this understanding. Graded dose–response curves depict the spectrum of a biological reaction to different doses within an individual, indicating that as the drug dosage increases, so does the intensity of the response. On the other hand, quantal dose–response relationships...
Dose-Response Relationship: Overview01:03

Dose-Response Relationship: Overview

Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...
Dose-Response Relationship: Selectivity and Specificity01:25

Dose-Response Relationship: Selectivity and Specificity

Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and β2-adrenergic receptors...
Testing a Claim about Population Proportion01:24

Testing a Claim about Population Proportion

A complete procedure for testing a claim about a population proportion is provided here.
There are two methods of testing a claim about a population proportion: (1) Using the sample proportion from the data where a binomial distribution is approximated to the normal distribution and (2) Using the binomial probabilities calculated from the data.
The first method uses normal distribution as an approximation to the binomial distribution. The requirements are as follows: sample size is large...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy of Prophylactic Laser treatment of Lattice Degeneration in the Fellow Eyes of Patients with Retinal Break(s) in the First Eye.

Ophthalmology. Retina·2026
Same author

Factors associated with persistent vision loss in eyes with diabetic macular edema and non-proliferative diabetic retinopathy after lost-to-follow-up.

Retina (Philadelphia, Pa.)·2026
Same author

The CRT-Estimands Framework for Cluster Randomized Trials.

JAMA·2026
Same author

CRT-Estimands Framework: consensus based extension of the ICH E9(R1) addendum for cluster randomised trials.

BMJ (Clinical research ed.)·2026
Same author

Clinical Outcomes of Ocular Toxoplasmosis-Associated Rhegmatogenous and Tractional Retinal Detachment.

Journal of vitreoretinal diseases·2026
Same author

Influence of Social Determinants of Health on Presenting Visual Acuity in Retinal Vein Occlusions.

Ophthalmology science·2026
Same journal

Comparison of Different Methods for the Meta-Analysis of Diagnostic Test Accuracy Studies-A Simulation Study.

Biometrical journal. Biometrische Zeitschrift·2026
Same journal

When to Adjust for Multiple Testing: A Unifying Guiding Principle.

Biometrical journal. Biometrische Zeitschrift·2026
Same journal

Ensuring Quality in Preclinical Research: The Importance of Being Human.

Biometrical journal. Biometrische Zeitschrift·2026
Same journal

Addressing Cluster-Level Treatment Effect Heterogeneity in Sample Size Determination for Hierarchical 2 × 2 Factorial Designs.

Biometrical journal. Biometrische Zeitschrift·2026
Same journal

A Multiple Imputation Approach to Distinguish Curative From Life-Prolonging Effects in the Presence of Missing Covariates.

Biometrical journal. Biometrische Zeitschrift·2026
Same journal

Tests for Categorical Data Beyond Pearson: A Distance Covariance and Energy Distance Approach.

Biometrical journal. Biometrische Zeitschrift·2026
See all related articles

Related Experiment Video

Updated: Jul 3, 2026

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification (ADCI) and Dose Estimation
10:33

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification (ADCI) and Dose Estimation

Published on: September 4, 2017

Dose finding - a challenge in statistics.

Frank Bretz1, Jason Hsu, José Pinheiro

  • 1Clinical Information Sciences, Novartis Pharma AG, CH-4002 Basel, Switzerland. frank.bretz@novartis.com

Biometrical Journal. Biometrische Zeitschrift
|July 30, 2008
PubMed
Summary
This summary is machine-generated.

Determining the correct drug dose is crucial for safety and efficacy in pharmaceutical development. This paper reviews statistical methods for definitive dose finding studies in Phase II/III clinical trials.

More Related Videos

The Use of Pharmacological-challenge fMRI in Pre-clinical Research: Application to the 5-HT System
11:27

The Use of Pharmacological-challenge fMRI in Pre-clinical Research: Application to the 5-HT System

Published on: April 25, 2012

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents (HPHC)
11:38

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents (HPHC)

Published on: May 10, 2016

Related Experiment Videos

Last Updated: Jul 3, 2026

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification (ADCI) and Dose Estimation
10:33

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification (ADCI) and Dose Estimation

Published on: September 4, 2017

The Use of Pharmacological-challenge fMRI in Pre-clinical Research: Application to the 5-HT System
11:27

The Use of Pharmacological-challenge fMRI in Pre-clinical Research: Application to the 5-HT System

Published on: April 25, 2012

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents (HPHC)
11:38

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents (HPHC)

Published on: May 10, 2016

Area of Science:

  • Pharmacology
  • Biostatistics
  • Drug Development

Background:

  • Characterizing dose-response relationships is vital for pharmaceutical development.
  • Incorrect dose selection can lead to safety issues or ineffectiveness.
  • Dose finding studies are critical for advancing drugs to confirmatory trials.

Purpose of the Study:

  • To review statistical designs and analysis methods for definitive dose finding studies.
  • To focus on Phase II and III clinical trials.
  • To provide an overview of multiple comparison procedures, modeling, and hybrid methods.

Main Methods:

  • Review of statistical methodologies for dose finding.
  • Description of multiple comparison procedures.
  • Explanation of modeling approaches and hybrid methods.
  • Inclusion of an outlook on adaptive dose finding.

Main Results:

  • The paper illustrates statistical methods using a real data example.
  • It provides a brief overview of relevant software for dose finding analysis.
  • Key statistical approaches for optimizing dose selection are presented.

Conclusions:

  • Effective dose finding is essential for successful drug development.
  • Statistical methods are crucial for ensuring drug safety and efficacy.
  • This review offers guidance on selecting appropriate statistical approaches for dose finding studies.